Motley Fool Australia

Amplia Therapeutics Ltd (ASX: ATX) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $29.66 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 107.86 million
Earnings per share -0.031
Dividend per share N/A
Year To Date Return 16.67%
Earnings Yield N/A
Franking N/A

Amplia Therapeutics Ltd (ASX: ATX) Latest News

woman in lab coat conducting testing representing mesoblast share price

Here’s why the Amplia (ASX:ATX) share price is up 9% today

More »

Buy shares

Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake

More »

US

US congressman resigns over ASX insider trading penny stock scandal

More »

US

ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)

More »

Brokers trading shares

Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter

More »

Were these the 3 worst shares on the ASX in 2017?

More »

winner, loser

These are the 5 biggest losers on the All Ordinaries in the last 12 months

More »

Investing ideas

One crucial thing to consider before investing in risky biotech shares

More »

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size
 

About Amplia Therapeutics Ltd (ASX: ATX)

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
26 Feb 2021 $0.28 $-0.01 -3.57% 222,273 $0.28 $0.28 $0.26
25 Feb 2021 $0.28 $0.01 3.70% 57,734 $0.27 $0.28 $0.27
24 Feb 2021 $0.27 $-0.01 -3.64% 1,789 $0.27 $0.27 $0.27
23 Feb 2021 $0.28 $0.00 0.00% 39,962 $0.28 $0.28 $0.28
22 Feb 2021 $0.28 $-0.01 -3.51% 127,876 $0.29 $0.29 $0.27
19 Feb 2021 $0.29 $0.00 0.00% 56,590 $0.29 $0.29 $0.28
17 Feb 2021 $0.29 $0.02 7.41% 371,454 $0.29 $0.30 $0.29
16 Feb 2021 $0.27 $-0.01 -3.57% 77,472 $0.29 $0.29 $0.27
15 Feb 2021 $0.28 $0.01 3.70% 52,000 $0.28 $0.29 $0.28
12 Feb 2021 $0.27 $-0.01 -3.64% 18,687 $0.27 $0.27 $0.27
11 Feb 2021 $0.28 $0.01 3.70% 150,721 $0.27 $0.29 $0.27
10 Feb 2021 $0.27 $0.00 0.00% 48,233 $0.27 $0.27 $0.27
09 Feb 2021 $0.27 $-0.01 -3.64% 78,673 $0.28 $0.28 $0.27
08 Feb 2021 $0.28 $0.01 3.70% 109,568 $0.27 $0.28 $0.26
05 Feb 2021 $0.27 $0.01 3.85% 178,098 $0.27 $0.27 $0.26
04 Feb 2021 $0.26 $-0.01 -3.70% 88,785 $0.26 $0.27 $0.26
03 Feb 2021 $0.27 $0.01 3.85% 156,745 $0.26 $0.27 $0.26
02 Feb 2021 $0.26 $0.00 0.00% 67,398 $0.26 $0.26 $0.26
01 Feb 2021 $0.26 $-0.01 -3.77% 187,639 $0.27 $0.27 $0.26
29 Jan 2021 $0.27 $-0.01 -3.70% 122,313 $0.27 $0.28 $0.27
28 Jan 2021 $0.27 $-0.03 -10.17% 391,247 $0.29 $0.29 $0.27
Show more

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Sep 2020 Christopher Burns Issued 197 $25,000
18 Sep 2020 Warwick Tong Issued 413 $52,500
18 Sep 2020 Robert Peach Issued 275 $35,000
04 Aug 2020 John Lambert Issued 120 $12,000
04 Aug 2020 Warwick Tong Issued 150 $15,000
13 Jul 2020 Warwick Tong Issued 200 $20,000


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Andrew John Cooke Company Secretary Oct 2013
Dr John Lambert Chief Executive Officer,Managing Director Jun 2019
Dr Robert Peach Non-Executive Director Sep 2015
Dr Warwick Bonner Tong Non-Executive Director,Non-Executive Chairman May 2018
Dr Christopher John Burns Non-Executive Director May 2018
Jeff Carter Chief Financial Officer (CFO)

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 17,398,080 20.15%
Bond Street Custodians Limited <LAM1 - D08047 A/C> 7,500,000 8.69%
Citicorp Nominees Pty Limited 7,397,724 8.57%
CTXT Pty Ltd 4,514,468 5.23%
Elk River Holdings Pty Ltd 2,942,142 3.41%
Christopher John Burns 2,275,237 2.64%
34th Avenue Pty Ltd <Devlin Family A/C> 2,215,237 2.57%
Warwick Tong 1,941,428 2.25%
Mark Sullivan <AEMS Consulting A/C> 1,661,428 1.92%
Merrill Lynch (Australia) Nominees Pty Limited 1,534,712 1.78%
Cancer Research Technology Limited 1,360,524 1.58%
Cofactor LLC 1,000,000 1.16%
HWH Power Pty Ltd <HWH Super Fund A/C> 950,000 1.10%
Margaret Frame 923,016 1.07%
Calama Holdings Pty Ltd <Mambat Super Fund A/C> 875,000 1.01%
Symington Pty Ltd 710,000 0.82%
Mr Andrew Podolak 610,000 0.71%
Yelwac Pty Ltd <The Cawley Superfund No2 A/C> 600,000 0.69%
Mr Li Sun 580,000 0.67%
Mrs Patricia Watkins + Mr John Phibbs + Mr Graeme Halse 566,625 0.66%
Show more